InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.730 0.99 (56.90%)+
Announcement
Release
22 Aug 2025 9:00AM
Price at Release
$1.740
Full Release
download
Summary
Cogstate Limited released its Appendix 4E and Annual Report for the year ended 30 June 2023, providing an overview of its financial performance and operations. The company reported a decrease in revenue compared to the previous year, mainly due to lower Clinical Trials revenue, though Healthcare revenue continued to grow. Despite the revenue decline, Cogstate maintained a strong cash balance and a positive net asset position. The report highlights the company's ongoing investment in research and development, its partnership with Eisai in the Alzheimer's disease space, and strategic priorities to expand digital cognitive assessment in both clinical trials and healthcare markets. The Directors’ Report includes details on corporate governance, remuneration, risk management, and outlook for future growth, emphasizing the company’s commitment to innovation and global expansion.
Key Points
  • Cogstate Limited reported a decrease in total revenue for FY2023, primarily due to lower Clinical Trials revenue.
  • Healthcare segment revenue grew, reflecting continued momentum in cognitive assessment and digital health solutions.
  • The company maintained a strong cash position and net assets, ensuring financial stability.
  • Ongoing partnership with Eisai in Alzheimer's disease and digital cognitive assessment remains a strategic focus.
  • Investment in research and development continued to support innovation and product enhancement.
  • Directors’ Report covers corporate governance, risk management, and executive remuneration.
  • Cogstate’s strategic priorities include expanding clinical trial solutions and healthcare offerings globally.
  • The company outlook emphasizes growth through innovation, global partnerships, and market expansion.
  • The Appendix 4E summarizes statutory results, audit opinions, and key financial metrics for the year ended 30 June 2023.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.